{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T04:10:54Z","timestamp":1787890254832,"version":"build-2784847793"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2015,4,8]],"date-time":"2015-04-08T00:00:00Z","timestamp":1428451200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1007\/s00520-015-2714-9","type":"journal-article","created":{"date-parts":[[2015,4,7]],"date-time":"2015-04-07T05:40:43Z","timestamp":1428385243000},"page":"3229-3237","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial"],"prefix":"10.1007","volume":"23","author":[{"given":"Sameer","family":"Bakhshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Batra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bivas","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Dhawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reeja","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishnubhatla","family":"Sreenivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,4,8]]},"reference":[{"issue":"23","key":"2714_CR1","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra0706547","volume":"358","author":"PJ Hesketh","year":"2008","unstructured":"Hesketh PJ (2008) Chemotherapy-induced nausea and vomiting. N Engl J Med 358(23):2482\u20132494","journal-title":"N Engl J Med"},{"issue":"9","key":"2714_CR2","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1200\/JCO.1999.17.9.2971","volume":"17","author":"RJ Gralla","year":"1999","unstructured":"Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW et al (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol Off J Am Soc Clin Oncol 17(9):2971\u20132994","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"6","key":"2714_CR3","doi-asserted-by":"crossref","first-page":"e414","DOI":"10.3747\/co.19.1074","volume":"19","author":"N Bouganim","year":"2012","unstructured":"Bouganim N, Dranitsaris G, Hopkins S, Vandermeer L, Godbout L, Dent S et al (2012) Prospective validation of risk prediction indexes for acute and delayed chemotherapy-induced nausea and vomiting. Curr Oncol 19(6):e414\u2013e421","journal-title":"Curr Oncol"},{"issue":"2 Suppl 1","key":"2714_CR4","first-page":"1","volume":"11","author":"SM Grunberg","year":"2003","unstructured":"Grunberg SM, Slusher B, Rugo HS (2003) Emerging treatments in chemotherapy-induced nausea and vomiting. Clin Adv Hematol Oncol 11(2 Suppl 1):1\u201318, quiz 2 p following 18","journal-title":"Clin Adv Hematol Oncol"},{"issue":"5","key":"2714_CR5","first-page":"497","volume":"15","author":"L Cohen","year":"2007","unstructured":"Cohen L, de Moor CA, Eisenberg P, Ming EE, Hu H (2007) Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer Off J Multinatl Assoc Support Care Cancer 15(5):497\u2013503","journal-title":"Support Care Cancer Off J Multinatl Assoc Support Care Cancer"},{"issue":"11","key":"2714_CR6","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1200\/JCO.1988.6.11.1746","volume":"6","author":"JL Richardson","year":"1988","unstructured":"Richardson JL, Marks G, Levine A (1988) The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy. J Clin Oncol Off J Am Soc Clin Oncol 6(11):1746\u20131752","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"3 Suppl 4","key":"2714_CR7","first-page":"32","volume":"12","author":"GR Morrow","year":"1998","unstructured":"Morrow GR, Roscoe JA, Hickok JT, Stern RM, Pierce HI, King DB et al (1998) Initial control of chemotherapy-induced nausea and vomiting in patient quality of life. Oncology (Williston Park) 12(3 Suppl 4):32\u201337","journal-title":"Oncology (Williston Park)"},{"issue":"9","key":"2714_CR8","first-page":"1278","volume":"41","author":"DG Warr","year":"2005","unstructured":"Warr DG, Grunberg SM, Gralla RJ, Hesketh PJ, Roila F, de Wit R et al (2005) The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from 2 randomised, double-blind, placebo controlled trials. Eur J Cancer Oxf Engl 1990 41(9):1278\u20131285","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"2714_CR9","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Antiemesis\u2014antiemesis.pdf [Internet]. [cited 2014 Jan 1]. Available from: http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf"},{"issue":"Suppl 5","key":"2714_CR10","doi-asserted-by":"crossref","first-page":"v232","DOI":"10.1093\/annonc\/mdq194","volume":"21","author":"F Roila","year":"2010","unstructured":"Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E et al (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol Off J Eur Soc Med Oncol ESMO 21(Suppl 5):v232\u2013v243","journal-title":"Ann Oncol Off J Eur Soc Med Oncol ESMO"},{"issue":"31","key":"2714_CR11","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1200\/JCO.2010.34.4614","volume":"29","author":"E Basch","year":"2011","unstructured":"Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR et al (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol Off J Am Soc Clin Oncol 29(31):4189\u20134198","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"2714_CR12","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/pbc.21811","volume":"52","author":"L Gore","year":"2009","unstructured":"Gore L, Chawla S, Petrilli A, Hemenway M, Schissel D, Chua V et al (2009) Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability. Pediatr Blood Cancer 52(2):242\u2013247","journal-title":"Pediatr Blood Cancer"},{"key":"2714_CR13","doi-asserted-by":"crossref","unstructured":"Bodge M, Shillingburg A, Paul S, Biondo L (2013) Safety and efficacy of aprepitant for chemotherapy-induced nausea and vomiting in pediatric patients: a prospective, observational study. Pediatr Blood Cancer","DOI":"10.1002\/pbc.24901"},{"issue":"7","key":"2714_CR14","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/pbc.24508","volume":"60","author":"LL Dupuis","year":"2013","unstructured":"Dupuis LL, Boodhan S, Holdsworth M, Robinson PD, Hain R, Portwine C et al (2013) Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer 60(7):1073\u20131082","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"2714_CR15","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/pbc.23114","volume":"57","author":"LL Dupuis","year":"2011","unstructured":"Dupuis LL, Boodhan S, Sung L, Portwine C, Hain R, McCarthy P et al (2011) Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer 57(2):191\u2013198","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"2714_CR16","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/pbc.22778","volume":"56","author":"AK Pillai","year":"2011","unstructured":"Pillai AK, Sharma KK, Gupta YK, Bakhshi S (2011) Anti-emetic effect of ginger powder versus placebo as an add-on therapy in children and young adults receiving high emetogenic chemotherapy. Pediatr Blood Cancer 56(2):234\u2013238","journal-title":"Pediatr Blood Cancer"},{"key":"2714_CR17","unstructured":"Nausea and Vomiting (PDQ\u00ae)\u2014National Cancer Institute [Internet]. [cited 2014 Jan 1]. Available from: http:\/\/www.cancer.gov\/cancertopics\/pdq\/supportivecare\/nausea\/HealthProfessional\/page1\/AllPages"},{"issue":"12","key":"2714_CR18","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1002\/cncr.11433","volume":"97","author":"S Poli-Bigelli","year":"2003","unstructured":"Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A et al (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97(12):3090\u20133098","journal-title":"Cancer"},{"issue":"22","key":"2714_CR19","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.1200\/JCO.2003.01.095","volume":"21","author":"PJ Hesketh","year":"2003","unstructured":"Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R et al (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin\u2014the Aprepitant Protocol 052 Study Group. J Clin Oncol Off J Am Soc Clin Oncol 21(22):4112\u20134119","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"4","key":"2714_CR20","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/cncr.21222","volume":"104","author":"RJ Gralla","year":"2005","unstructured":"Gralla RJ, de Wit R, Herrstedt J, Carides AD, Ianus J, Guoguang-Ma J et al (2005) Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two phase III randomized clinical trials. Cancer 104(4):864\u2013868","journal-title":"Cancer"},{"issue":"7","key":"2714_CR21","doi-asserted-by":"crossref","first-page":"e268","DOI":"10.1097\/MPH.0b013e3181e5e1af","volume":"32","author":"MR Choi","year":"2010","unstructured":"Choi MR, Jiles C, Seibel NL (2010) Aprepitant use in children, adolescents, and young adults for the control of chemotherapy-induced nausea and vomiting (CINV). J Pediatr Hematol Oncol 32(7):e268\u2013e271","journal-title":"J Pediatr Hematol Oncol"},{"issue":"2","key":"2714_CR22","first-page":"127","volume":"19","author":"A Shillingburg","year":"2014","unstructured":"Shillingburg A, Biondo L (2014) Aprepitant and fosaprepitant use in children and adolescents at an academic medical center. J Pediatr Pharmacol Ther JPPT Off J PPAG 19(2):127\u2013131","journal-title":"J Pediatr Pharmacol Ther JPPT Off J PPAG"},{"issue":"5","key":"2714_CR23","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1177\/1043454214531090","volume":"31","author":"K Duggin","year":"2014","unstructured":"Duggin K, Tickle K, Norman G, Yang J, Wang C, Cross SJ et al (2014) Aprepitant reduces chemotherapy-induced vomiting in children and young adults with brain tumors. J Pediatr Oncol Nurs Off J Assoc Pediatr Oncol Nurses 31(5):277\u2013283","journal-title":"J Pediatr Oncol Nurs Off J Assoc Pediatr Oncol Nurses"},{"issue":"6","key":"2714_CR24","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s11096-013-9842-4","volume":"35","author":"TGM Bauters","year":"2013","unstructured":"Bauters TGM, Verlooy J, Robays H, Benoit Y, Laureys G (2013) Emesis control by aprepitant in children and adolescents with chemotherapy. Int J Clin Pharm 35(6):1021\u20131024","journal-title":"Int J Clin Pharm"},{"issue":"17","key":"2714_CR25","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/jnci\/djs335","volume":"104","author":"LV Santos dos","year":"2012","unstructured":"dos Santos LV, Souza FH, Brunetto AT, Sasse AD, da Silveira Nogueira Lima JP (2012) Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review. J Natl Cancer Inst 104(17):1280\u20131292","journal-title":"J Natl Cancer Inst"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-015-2714-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-015-2714-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-015-2714-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T01:34:19Z","timestamp":1566524059000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-015-2714-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,8]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["2714"],"URL":"https:\/\/doi.org\/10.1007\/s00520-015-2714-9","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,8]]}}}